Leprosy, also called Hansen’s disease, is a chronic bacterial infection caused by Mycobacterium leprae, a slow-growing organism with an unusual preference for skin and peripheral nerves. Despite its ancient reputation as an untreatable curse, leprosy is curable with a combination of antibiotics, and most people exposed to the bacterium never develop symptoms. The disease persists today because of delayed diagnosis, limited access to care in high-burden regions, and stubborn social stigma that discourages people from seeking help early.
What Causes Leprosy
M. leprae is a peculiar pathogen. It cannot be grown in a standard laboratory culture dish, which has slowed research for over a century. It reproduces extremely slowly compared to other bacteria, dividing roughly once every two weeks. This sluggish pace is one reason the disease takes so long to show itself after infection.
The bacterium has a strong affinity for Schwann cells, the cells that form a protective sheath around peripheral nerves. Research has shown that M. leprae can reprogram adult Schwann cells into a stem-cell-like state, effectively hijacking them to help the infection spread through the body.1PubMed Central. Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection This nerve-targeting behavior explains why nerve damage is such a central feature of the disease, often causing numbness, weakness, and the injuries that follow when a person can no longer feel pain in their hands and feet.
How It Spreads
Leprosy is far less contagious than most people assume. Prolonged, close contact with an untreated person is usually required. The main route is thought to be airborne droplets from the nose and upper respiratory tract. Studies using molecular detection methods have found that both nasal secretions and skin surfaces of untreated patients with heavy bacterial loads shed M. leprae into the environment, putting close household contacts at risk.2PubMed. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR Once someone begins treatment, they quickly become noninfectious.
An unexpected wrinkle in the transmission story comes from armadillos. Nine-banded armadillos in the southern United States and parts of Brazil are naturally infected with M. leprae, and molecular studies have confirmed zoonotic transmission to humans. A study of wild armadillos and leprosy patients in the southeastern U.S. found that a unique M. leprae strain was present in both the animals and roughly two-thirds of patients in areas where armadillo contact was possible.3PubMed Central. Probable zoonotic leprosy in the southern United States In parts of Brazil, people who hunt, butcher, or eat armadillo meat face a higher risk of infection.4PLOS Neglected Tropical Diseases. Evidence of zoonotic leprosy in Pará, Brazilian Amazon, and risks associated with human contact or consumption of armadillos Surveillance has found infection in about 16% of armadillos tested, and the geographic range of this zoonotic transmission appears to be expanding.5PubMed Central. Zoonotic Leprosy in the Southeastern United States
This armadillo connection matters because it means leprosy cannot be eliminated solely by treating human cases. As long as animal reservoirs exist, occasional new infections will continue to appear, even in countries where person-to-person transmission is rare.
Why Most People Never Get Sick
Even among people who are exposed to M. leprae, the vast majority fight it off without ever developing symptoms. Estimates suggest that upward of 95% of the human population has a natural resistance to the bacterium. Whether someone actually becomes ill depends heavily on their genetic makeup, particularly the genes governing their immune response.
Decades of genetic research have identified variants in several immune-related genes that influence susceptibility to leprosy, the clinical form a person develops, and even the likelihood of experiencing inflammatory reactions during the course of disease.6PubMed Central. Genetic Susceptibility to Leprosy-From Classic Immune-Related Candidate Genes to Hypothesis-Free, Whole Genome Approaches These include genes involved in pathogen recognition and bacterial uptake. Small variations in these genes can alter either the risk of developing leprosy altogether or the severity once it takes hold.7PubMed. Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome Genome-wide studies have also turned up susceptibility genes that are not classically linked to immune function, hinting at mechanisms researchers do not yet fully understand.
Symptoms and Clinical Forms
Leprosy’s incubation period is remarkably long, typically three to five years but sometimes stretching to two decades. Because M. leprae grows so slowly, a person can be infected for years without noticing anything wrong. When symptoms do appear, they usually begin with skin changes and nerve problems.
The earliest signs are often pale or reddish patches on the skin that have reduced sensation to touch, heat, or pain. If the disease progresses, nerve thickening can become noticeable, especially in the elbows, wrists, and behind the knees. Muscle weakness in the hands and feet may develop, and without treatment, the loss of sensation leads to repeated unnoticed injuries and secondary infections that cause the tissue damage historically associated with the disease.
Clinicians classify leprosy along a spectrum based on the immune response. At one end is the tuberculoid form, where the body mounts a strong immune reaction that limits bacterial growth but can destroy nerve tissue in the process. At the other end is the lepromatous form, where the immune response is weak and bacteria multiply freely throughout the skin, nerves, and other tissues. In the lepromatous type, bacteria are easily found in Schwann cells, blood vessel linings, and immune cells, while the tuberculoid type features immune-driven clusters of cells that destroy both the bacteria and surrounding nerve fibers.8Handbook of Clinical Neurology. Leprous neuropathy Between these poles lie borderline forms that share features of both extremes and can shift over time.
For treatment purposes, the World Health Organization simplifies this spectrum into two practical categories: paucibacillary (few bacteria, typically fewer skin lesions) and multibacillary (many bacteria, more widespread disease). This distinction determines which drug regimen a patient receives and for how long.
Leprosy Reactions
One of the trickiest aspects of leprosy care is managing reactions, which are sudden inflammatory episodes that can occur before, during, or even after treatment. These reactions are a major source of nerve damage and disability.
Type 1 reactions (also called reversal reactions) involve a flare-up of inflammation in existing skin lesions and nerve trunks, causing swelling, redness, and sometimes rapid loss of nerve function.9PubMed Central. Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy These occur in the borderline forms of the disease and represent a shift in immune activity against the bacterium. Type 2 reactions, called erythema nodosum leprosum, are seen in the lepromatous end of the spectrum and produce painful, inflamed nodules under the skin along with fever and general illness.
Corticosteroids are considered the most effective treatment for both types of reaction, and multidrug therapy is continued throughout. For patients who do not respond adequately, clofazimine or thalidomide may be added, particularly for type 2 reactions.10Infectious Diseases in Clinical Practice. Clinical Management of Leprosy Reactions Early recognition of reactions is critical because prompt treatment with steroids can prevent permanent nerve damage. Unfortunately, in settings with limited health-care access, reactions are often identified too late.
How Leprosy Is Diagnosed
Diagnosis still relies primarily on clinical examination: finding characteristic skin lesions with loss of sensation, thickened peripheral nerves, or evidence of M. leprae in skin samples. A slit skin smear, where a small incision is made and tissue fluid is examined under a microscope, is the classic laboratory test. It works well for multibacillary cases, but it misses the majority of paucibacillary patients because their bacterial load is extremely low.
Molecular methods like PCR have changed the diagnostic landscape. One study found that PCR had a sensitivity of about 85% across all clinical forms of leprosy, with complete specificity, meaning no false positives from other skin conditions or other mycobacterial infections.11PubMed Central. qPCR detection of Mycobacterium leprae in biopsies and slit skin smear of different leprosy clinical forms The real advantage shows up in paucibacillary disease: PCR detected the bacterium in about 75% of paucibacillary cases, compared to under 2% for the traditional slit skin smear.12PubMed. Diagnosing leprosy: revisiting the role of the slit-skin smear with critical analysis of the applicability of polymerase chain reaction in diagnosis In practical terms, this means PCR can confirm cases that would otherwise be diagnosed only on clinical suspicion, reducing the chances of misdiagnosis.
Misdiagnosis remains a real problem. Leprosy can mimic a range of other skin and neurological conditions, and in regions where it is rare, doctors may not consider it. This is especially true outside traditional endemic areas, where imported or armadillo-linked cases can go unrecognized for months or years.
Modern Treatment
The backbone of leprosy treatment is multidrug therapy, or MDT, recommended by the World Health Organization since the 1980s. The standard combination includes rifampicin, dapsone, and clofazimine. Paucibacillary patients typically take a six-month course, while multibacillary patients are treated for twelve months. A large network meta-analysis pooling data from 60 controlled trials confirmed that this regimen is effective, though the authors noted the evidence base could be stronger.13PubMed. Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis
Alternative regimens have been tested. Rifampicin-ofloxacin-minocycline, known as ROM, was explored as a shorter or simpler option, especially for single-lesion paucibacillary disease. However, systematic reviews found ROM was no better than standard MDT.14PubMed Central. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis The standard three-drug combination remains the first-line treatment worldwide.
MDT is provided free of charge globally through a donation program, which has been instrumental in making treatment accessible. Once treatment begins, patients become noninfectious within days, and full courses achieve cure in the vast majority of cases. The drugs are generally well tolerated, though dapsone can occasionally cause anemia and clofazimine produces a reversible brownish skin discoloration that some patients find distressing.
Drug Resistance
Because M. leprae cannot be grown in standard lab cultures, detecting drug resistance has historically been difficult. Molecular surveillance has revealed that resistance does occur, driven by mutations in specific genes targeted by each drug in the MDT regimen.15PubMed Central. Unraveling Drug Resistance in Mycobacterium leprae: Exploring Genetic Mutations to Enhance Treatment Strategies for Human Leprosy Resistance to rifampicin, the most powerful drug in the combination, is the greatest concern, because without it the remaining drugs are much less effective on their own.
So far, drug resistance in leprosy remains uncommon relative to the total number of cases, but it is not negligible. The WHO runs a global surveillance network to track resistance, and the data reinforce the importance of patients completing their full course of treatment. Incomplete treatment is the single biggest driver of resistance in any bacterial infection, and leprosy is no exception. Additional resistance mechanisms beyond target-gene mutations, including bacterial efflux pumps and cell wall changes, have been identified, which means the problem could worsen if vigilance lapses.
Preventing Leprosy in Contacts
If you live in a household with someone diagnosed with leprosy, your risk of developing the disease is substantially higher than the general population’s. Two prevention strategies have strong evidence behind them.
BCG vaccination, originally developed against tuberculosis, provides partial protection against leprosy as well. A meta-analysis found that BCG offers greater protection among household contacts of leprosy patients than in the general population, though its effectiveness wanes over time.16PubMed Central. The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis The other tool is single-dose rifampicin given to contacts of newly diagnosed patients. This simple, inexpensive intervention showed about a 57% protective effect in the first two years, with rare side effects and negligible risk of inducing drug resistance.
Combining the two strategies appears to be even better. One study found that when BCG vaccination and rifampicin prophylaxis were used together, the protective effect reached about 80%.17PubMed. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention This combination approach is now being integrated into control programs in several high-burden countries and represents one of the most promising avenues for driving new case numbers down further.
Coinfection With HIV
In parts of sub-Saharan Africa, South Asia, and Brazil where both diseases are common, leprosy and HIV occasionally occur in the same person. Managing both simultaneously poses challenges: the pill burden of antiretroviral drugs on top of MDT is heavy, drug interactions and overlapping side effects complicate care, and diagnostic confusion can arise because HIV-related skin conditions mimic leprosy.18PubMed Central. Human immunodeficiency virus and leprosy coinfection: challenges in resource-limited setups
A distinctive pattern has emerged since the widespread rollout of antiretroviral therapy. As a patient’s immune system recovers on HIV treatment, the newly revived immune response can “unmask” a previously silent leprosy infection or trigger a type 1 reaction, a phenomenon classified as immune reconstitution inflammatory syndrome.19PubMed. Leprosy and HIV coinfection: a critical approach Clinicians in coinfection-prone regions need to keep leprosy on the radar when patients starting antiretrovirals develop unexpected skin or nerve symptoms.
Where Leprosy Persists and Why
Global leprosy cases have fallen dramatically since the introduction of MDT, from millions of active cases in the mid-twentieth century to roughly 200,000 new cases reported annually in recent years. India, Brazil, and Indonesia together account for the vast majority of those new cases. Modeling studies have projected continued declines at the national level, but high-endemic pockets within those countries have proven stubbornly resistant to control.20PubMed Central. Global elimination of leprosy by 2020: are we on track? Regions like Chhattisgarh in India and Pará in Brazil were projected to miss elimination targets by five to ten years, and the disease’s extremely long incubation period means that infections acquired today may not surface clinically until the 2030s or beyond.
Several factors sustain transmission in these hotspots: poverty and crowded living conditions, under-resourced health systems, the long silent incubation period that allows untreated patients to spread the bacterium for years, and social stigma that keeps people from presenting for diagnosis. Elimination campaigns that focus solely on treating diagnosed cases will always be chasing the tail of a very long transmission chain.
The Stigma Problem
Leprosy carries one of the heaviest stigma burdens of any disease in history. For centuries it was treated as divine punishment, and affected individuals were forcibly isolated in colonies that persisted, in some places, well into the twentieth century. The international community has only recently recognized leprosy-related stigma as a formal human rights issue.21PubMed Central. Initiatives to address leprosy as a human rights issue through the mandate of UN Special Rapporteur: Achievements and challenges
One effort to reduce stigma has been renaming the disease. The term “Hansen’s disease,” after the Norwegian physician who identified M. leprae in 1873, has been adopted in clinical and policy circles partly to distance the condition from centuries of fearful connotation.22PubMed Central. Mycobacterium leprae: A historical study on the origins of leprosy and its social stigma Whether the name change has meaningfully shifted public attitudes is debatable, but it reflects a broader acknowledgment that the language surrounding the disease matters. In some countries, discriminatory laws still exist, barring people with a history of leprosy from marriage, employment, or public transport, even after they are fully cured.
Stigma is not just a social justice issue; it is a clinical one. Fear of discrimination delays diagnosis, which extends the period of infectiousness and increases the risk of permanent disability. Any serious elimination strategy has to address stigma alongside antibiotics.
What Ancient DNA Reveals About the Disease’s Past
Leprosy has been with humanity for thousands of years, and recent advances in ancient DNA recovery have reshaped our understanding of how it spread. Analysis of medieval Scandinavian remains uncovered a strain of M. leprae previously found only in Asia, suggesting that the bacterium traveled from the Middle East to northern Europe much earlier than previously thought.23Journal of Archaeological Science. Ancient-DNA reveals an Asian type of Mycobacterium leprae in medieval Scandinavia Until that discovery, all European samples, ancient and modern, had belonged to a single genetic lineage.
Broader studies of ancient M. leprae genomes from across Europe have started connecting the dots between the bacterium’s population dynamics and major historical events, including the expansion of the Roman Empire and the beginning of regular transatlantic trade.24PubMed Central. Mycobacterium leprae diversity and population dynamics in medieval Europe from novel ancient genomes The story these genomes tell is one of a pathogen that moved with human migration and commerce, gaining new footholds wherever people traveled. Understanding these historical patterns is more than an academic exercise. It helps researchers model how M. leprae diversifies and spreads, including the interspecies transmissions between humans and animals that continue to complicate elimination efforts today.